AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients
Status:
Terminated
Trial end date:
2018-11-30
Target enrollment:
Participant gender:
Summary
This is a dose escalation study to evaluate Omacetaxine when given in combination with a
standard induction regimen of "7+3" (cytarabine for Days 1-7 and Idarubicin for Days 1-3) in
patients with newly diagnosed acute myelogenous leukemia (AML).